

REMARKS

Prior to the present amendments, claims 1-27 were pending. Claims 1-7, 9, 10 and 17-27 have been cancelled. Claims 11, 13 and 16 have been amended. Support for the amendments are found in Figures 5241 and 5242. No new matter has been added by the amendments. All amendments and cancellations have been made without prejudice or disclaimer. Applicants reserve the right to pursue cancelled subject matter in one or more continuing applications.

Election/Restrictions

Applicants have been requested to elect for examination in the present application one of Invention Groups, 1-6464, 6465-12928, 12929-19392, 19393-25857, 25858-32221, 32222-38686, 38687-45151, 45152-51615 or 51616-58080. Applicants have also been requested to elect a species of polypeptide for examination.


Applicants have herein elected Group 12929-19392, i.e., claims 11-16, as drawn to an antibody which specifically binds to a polypeptide of claim 8. Applicants further elect a polypeptide species of Claim 8 as identified by SEQ ID NO:2120 (Figure 5242). Claims 8 and 11-16 read on the elected species. Applicants' elections are made without traverse.

CONCLUSION

The present application is believed to be in *prima facie* condition for allowance, and an early action to that effect is respectfully solicited. Should there be any further issues outstanding, the Examiner is invited to contact the undersigned attorney at the telephone number shown below. Please charge any additional fees, including fees for additional extension of time, or credit overpayment to Deposit Account No. **07-1700** (referencing Attorney's Docket No. **GNE-0267 R1-1**).

Respectfully submitted,

Dated: July 11, 2008

By: 
Jeffrey O. Talkington (Reg. No. 58,381)

GOODWIN PROCTER LLP
135 Commonwealth Drive
Menlo Park, California 94025
Telephone: (650) 752-3100
Facsimile: (650) 853-1038